Article
30 September 2021 - by Dane Hansen, Andrew Bochner, Pamela M. Pelizzari
This report analyzes an Episode-based Benefit Plan (EBP) design that could be offered to members enrolled in commercial health plans.
Article
20 October 2020 - by Andrew Bochner, Jennifer Carioto, Luis Maldonado
How will COVID-19 affect a health plan’s medical loss ratio requirements in general and what are specific considerations for the commercial, Medicare Advantage, and Medicaid markets in 2020 and going forward?
Article
29 June 2020 - by Dane Hansen, Andrew Bochner, Emily DeAngelis
This paper examines the reported impact of COVID-19 on preliminary rate filings among six states and D.C. that have been publicly released as of June 15, 2020.
Article
27 March 2018 - by Andrew Bochner, Gabriela Dieguez, Bruce S. Pyenson
This report analyzes the impact of the per-prescription cost-sharing cap for non-catastrophic plans on projected prescription drug spending across the California individual and small group markets.
Article
22 August 2016 - by Warner Huh, Andrew Bochner, Kate Fitch
This paper analyzes commercial payer differences in the average costs and readmission rates between inpatient open hysterectomies and three types of outpatient hysterectomies: laparoscopic, laparoscopic assisted, and vaginal.
Article
22 August 2016 - by Warner Huh, Andrew Bochner, Kate Fitch
本紙では、入院開腹手術と3種類の外来手術（腹腔鏡子宮摘出術、腹腔鏡補助下子宮摘出術、膣式子宮摘出術）の平均コストと再入院率の民間保険支払者における違いを分析しています。
Article
06 August 2016 - by Andrew Bochner, Tyler Engel, Kate Fitch
本調査は、一般的に行われる４つの外科手術について、民間母集団における低侵襲手術と開腹手術の支払者コストの違いを分析するものです。
Article
06 August 2016 - by Andrew Bochner, Tyler Engel, Kate Fitch
This study analyzes the difference in payer costs between minimally invasive surgery and open surgery in a commercial population for four commonly performed elective surgical procedures.
Article
24 September 2015 - by Andrew Bochner, Ryan Cannon, Bruce S. Pyenson
HCV is the leading cause of both liver-related deaths and liver transplants in the United States. The high cost of new antiviral medicines has sparked debate over the cost of treating HCV, and some payers are seeking ways to minimize their spending on these medicines.
